Study Reveals Many Cancer Patients Miss Out on Genomic Testing for Targeted Treatments
A recent study published in JAMA Network Open highlights a significant gap in cancer treatment, revealing that many patients with advanced cancers do not receive genomic testing. This testing is crucial for identifying mutations that could be targeted by newer therapies. The study examined patients with five types of metastatic cancers and found that only about half received genetic sequencing. Disparities were noted, with patients of lower income, those on Medicare or Medicaid, and Black or Hispanic individuals being less likely to receive these tests. Despite advancements in cancer treatment, such as targeted therapies that exploit cancer mutations, the lack of genomic testing means many patients miss out on potentially life-saving treatments. 
